Cystic Fibrosis (CF) is a hereditary, systemic disease caused by mutations in the Cystic Fibrosis Transmembrane Regulator (CFTR) gene. This thesis focuses on class III (defective CFTR channel gating, e.g. G551D) and class II (defective CFTR folding/trafficking, e.g. F508del) mutations. Both cause severe symptoms. Assessed are effects of the potentiator ivacaftor (VX-770, KALYDECO^TM; Vertex Pharmaceuticals Inc.). Analyzed were biomarkers applicable to predict clinical efficacy. Data were taken from three previously performed randomized, double-blind, placebo controlled, multi-center trials. Patients with the G551D mutation, after receiving ivacaftor, showed significant improvements versus placebo: sweat chloride concentrations decreased s...
Cystic fibrosis (CF) is a recessive disorder caused by mutations in the gene that encodes the CF tra...
BACKGROUND: The ability to restore cystic fibrosis transmembrane regulator (CFTR) function with effe...
In a recent issue of CHEST (January 2013), Durmowicz et al 1 highlight the fi nding that despite imp...
AbstractBackgroundIvacaftor, a cystic fibrosis transmembrane regulator (CFTR) potentiator, decreased...
AbstractIvacaftor, a CFTR potentiator that enhances chloride transport by acting directly on CFTR to...
textabstractIn patients with cystic fibrosis, cystic fibrosis transmembrane conductance regulator (C...
Aim: The Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) potentiator ivacaftor (Kalydeco®...
Cystic Fibrosis (CF) is a rare monogenic multisystem disease caused by mutations in the cystic fibro...
Cystic Fibrosis (CF) is a rare monogenic multisystem disease caused by mutations in the cystic fibro...
In patients with cystic fibrosis, cystic fibrosis transmembrane conductance regulator (CFTR) biomark...
Rationale: Expanding the use of cystic fibrosis transmembrane conductance regulator (CFTR) potentiat...
Rationale: Expanding the use of cystic fibrosis transmembrane conductance regulator (CFTR) potentiat...
Introduction: Sweat chloride concentration, a biomarker of CFTR function, is an appropriate outcome ...
ABSTRACT: In patients with cystic fibrosis, cystic fibrosis transmembrane conductance regulator (CFT...
Background: Investigation of novel cystic fibrosis transmembrane conductance regulator (CFTR) potent...
Cystic fibrosis (CF) is a recessive disorder caused by mutations in the gene that encodes the CF tra...
BACKGROUND: The ability to restore cystic fibrosis transmembrane regulator (CFTR) function with effe...
In a recent issue of CHEST (January 2013), Durmowicz et al 1 highlight the fi nding that despite imp...
AbstractBackgroundIvacaftor, a cystic fibrosis transmembrane regulator (CFTR) potentiator, decreased...
AbstractIvacaftor, a CFTR potentiator that enhances chloride transport by acting directly on CFTR to...
textabstractIn patients with cystic fibrosis, cystic fibrosis transmembrane conductance regulator (C...
Aim: The Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) potentiator ivacaftor (Kalydeco®...
Cystic Fibrosis (CF) is a rare monogenic multisystem disease caused by mutations in the cystic fibro...
Cystic Fibrosis (CF) is a rare monogenic multisystem disease caused by mutations in the cystic fibro...
In patients with cystic fibrosis, cystic fibrosis transmembrane conductance regulator (CFTR) biomark...
Rationale: Expanding the use of cystic fibrosis transmembrane conductance regulator (CFTR) potentiat...
Rationale: Expanding the use of cystic fibrosis transmembrane conductance regulator (CFTR) potentiat...
Introduction: Sweat chloride concentration, a biomarker of CFTR function, is an appropriate outcome ...
ABSTRACT: In patients with cystic fibrosis, cystic fibrosis transmembrane conductance regulator (CFT...
Background: Investigation of novel cystic fibrosis transmembrane conductance regulator (CFTR) potent...
Cystic fibrosis (CF) is a recessive disorder caused by mutations in the gene that encodes the CF tra...
BACKGROUND: The ability to restore cystic fibrosis transmembrane regulator (CFTR) function with effe...
In a recent issue of CHEST (January 2013), Durmowicz et al 1 highlight the fi nding that despite imp...